Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Eribulin Treatment in Metastatic Breast Cancer: A Multicenter, Case-study Analysis

NCT02769364 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.

NCT NCT02769364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02769364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Eribulin Treatment in Metastatic Breast Cancer: A Multicenter, Case-study Analysis
Lead sponsor
Eisai Limited
Phase
Observational
Overall status
Completed
Start date
November 30, 2013
Completion date
June 30, 2014
Enrollment
45 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer